within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A07D_Antipropulsives.A07DA06_Eluxadoline;

model Eluxadoline
  extends Pharmacolibrary.Drugs.ATC.A.A07DA06;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A07DA06</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Eluxadoline is a mixed mu-opioid receptor agonist and delta-opioid receptor antagonist, utilized for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults. It acts locally in the gastrointestinal tract, reducing bowel contractions and inhibiting pain signals. Eluxadoline is approved by regulatory agencies such as the FDA and EMA.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic data based on healthy adult subjects following oral administration of eluxadoline 100 mg.</p><h4>References</h4><ol><li><p>Boinpally, R, &amp; Weissman, D (2023). Single-dose Pharmacokinetics of Eluxadoline in Healthy Participants With Normal Renal Function and Participants With Renal Impairment. <i>Clinical pharmacology in drug development</i> 12(2) 132–140. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.1204&quot;>10.1002/cpdd.1204</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36504331/&quot;>https://pubmed.ncbi.nlm.nih.gov/36504331</a></p></li><li><p>Boinpally, R, et al., &amp; Weissman, D (2022). An Open-Label Study to Evaluate the Effect of Eluxadoline on the Single-Dose Pharmacokinetics of Midazolam in Healthy Participants. <i>Clinical pharmacology in drug development</i> 11(11) 1341–1348. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.1150&quot;>10.1002/cpdd.1150</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35938453/&quot;>https://pubmed.ncbi.nlm.nih.gov/35938453</a></p></li><li><p>Levy-Cooperman, N, et al., &amp; Sellers, EM (2016). Abuse Potential and Pharmacodynamic Characteristics of Oral and Intranasal Eluxadoline, a Mixed μ- and κ-Opioid Receptor Agonist and δ-Opioid Receptor Antagonist. <i>The Journal of pharmacology and experimental therapeutics</i> 359(3) 471–481. DOI:<a href=&quot;https://doi.org/10.1124/jpet.116.236547&quot;>10.1124/jpet.116.236547</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27647873/&quot;>https://pubmed.ncbi.nlm.nih.gov/27647873</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Eluxadoline;
